20/20 BioLabs (formerly 2020 GeneSystems) develops and commercializes cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. Our advanced diagnostics leverage machine learning algorithms built on extensive real-world data, offering exceptional accuracy and convenience for individuals and providers.
We pioneer affordable, accurate, actionable tests that can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles.
(We call these advantages our “straight A’s)
OneTest™ for Cancer
Our protein tumor marker approach is the only multi-cancer early detection (MCED) blood test that:
- Detects multiple cancers including lung, pancreatic, ovarian, and liver at earlier, more treatable stages than competing, DNA based MCEDs.
- Starts at under $200, versus just under $1,000 from leading competitors.
- Can be collected at-home using the device painless, upper arm capillary blood collection.
Key Benefits
- AI-driven results: Enhanced accuracy through machine learning algorithms trained on data from tens of thousands of individuals tested months or years before being diagnosed with cancer.
- CAP Accredited & CLIA Licensed laboratory ensuring the highest standards of accuracy and reliability.
- Our MCED performed well in blinded studies conducted by the U.S. National Cancer Institute and our biomarker approach is supported by studies conducted by the MD Anderson Cancer Center and other leading academic medical centers.
COMING SOON
Introducing: OneTest for Longevity
Our newest test measures biomarkers of inflammation associated with chronic diseases including heart attacks, cancers, dementia, diabetes, and mental health. We offer specific guidance to improve diet and lifestyle to lower biomarkers and chronic inflammation to improve health aging.
Anticipated launch in Spring, supporting proactive disease prevention strategies aligned with “US Government-sanctioned initiatives”.
